Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
clinical trials
8
×
life sciences
national blog main
national top stories
roche
8
×
san francisco top stories
8
×
biotech
san francisco blog main
boston blog main
boston top stories
investing
national
amgen
cancer
deals
fda
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
biogen
biotech ipos
bristol-myers squibb
merck
new york blog main
pfizer
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
boston
boulder/denver blog main
boulder/denver top stories
bridgebio
detroit blog main
What
drug
cancer
bio
patients
roundup
data
fda
intended
ipo
medicines
new
pricing
roche
advanced
advantages
alliance
analytics
approval
approved
arrival
atrophy
award
bar
biofourmis
blood
blueprint
brings
bristol
broader
buy
calls
candidate
changing
color
company
crispr
currently
daily
days
death
Language
unset
8
×
Current search:
roche
×
photo
×
" san francisco top stories "
×
unset
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone